Anti-inflammatory effect of cholera toxin B subunit in experimental stroke by unknown
RESEARCH Open Access
Anti-inflammatory effect of cholera toxin B
subunit in experimental stroke
Lei Zhang1,2†, Yanxia Huang1†, Yinyao Lin2†, Yilong Shan2†, Sha Tan2, Wei Cai2, Haiyan Li2, Bingjun Zhang2,
Xuejiao Men2 and Zhengqi Lu2*
Abstract
Background: Cholera toxin B subunit (CTB) has multifaceted immunoregulatory functions. Immunity plays an
important role in the mechanism of stroke. However, little is known about whether CTB is beneficial for stroke.
Methods: CTB was administered intraperitoneally after ischemia to rats subjected to transient focal ischemia. Infarct
volumes, body weight loss, and neurologic deficits were measured. Cytokines, microglia/macrophage activation,
and transcriptional factors in the ischemic brain were tested. The mRNA expressions of IL-1β and TNF-α were tested
in the microglia/macrophage isolated from the ischemic hemisphere. γδT cells, IL-17-producing γδT cells, Th17 cells,
and regulatory T (Treg) cells in the ischemic brain were tested. γδT cells and Treg cells in the peripheral blood were
also evaluated.
Results: CTB reduced infarct volumes, neurologic deficits, and body weight loss after ischemia. At 24 h after
ischemia, CTB downregulated the levels of IL-1β, TNF-α, NF-kB p65, phosphorylated-ERK1/2, and microglia/macrophage
activation and suppressed NF-kB binding activity, but did not affect the level of ERK1/2. The mRNA expressions of IL-1β
and TNF-α in the microglia/macrophage isolated from the ischemic hemisphere were suppressed after CTB therapy. In
the ischemic hemisphere, CTB treatment reduced the levels of γδT cells, IL-17-producing γδT cells, and IL-17 at both 24
and 72 h after ischemia, while Th17 cells were not affected. After CTB treatment, the levels of Treg cells, TGF-β, and
IL-10 remained unchanged at 24 h and upregulated at 72 h after ischemia. Inactivation of Treg cells using anti-CD25
attenuated the increase of TGF-β and IL-10 induced by CTB at 72 h after ischemia. In the peripheral blood, CTB
increased Treg cells and suppressed γδT cells at 24 h after ischemia. And then at 72 h after ischemia, it increased Treg
cells but did not impact γδT cells. CTB had no effect on cytokines, transcription factors, infiltrating γδT cells, and Treg
cells in the brain of shams. In the peripheral blood of shams, CTB increased Treg cells at both 24 and 72 h, while it did
not affect γδT cells.
Conclusions: CTB decreased neurologic impairment and tissue injury after cerebral ischemia via its immunomodulatory
functions, including inhibiting microglia/macrophage activation, suppressing γδT cells, and inducing production of Treg
cells, thus regulating the secretion of related cytokines. Suppression of NF-kB and ERK1/2 pathways is involved in the
neuroprotective mechanism of CTB.
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Background
Ischemic stroke is a leading cause of disability and death
in the world [1]. Inflammation plays an important role
in the pathogenesis of ischemic stroke. Many anti-
inflammatory materials have proven successful in animal
models [2, 3], but attempts to translate them into clin-
ical application have been unsuccessful [4, 5]. So the
search for suitable anti-inflammatory substances is still
essential.
Cholera toxin is composed of one A subunit and five B
subunits. The cholera toxin B subunit (CTB) is devoid of
toxicity and capable of immunomodulation. Researchers
found that CTB could act as immunomodulatory mol-
ecule capable of suppressing Th1-associated immune re-
sponses [6]. Therefore, CTB began to be studied as a
therapy for T cell-mediated autoimmune diseases in ani-
mal models. Studies showed that coupling myelin basic
protein or insulin to CTB could be used as effective ther-
apies against experimental allergic encephalomyelitis in
the rats and diabetes in the nonobese diabetic (NOD)
mice, respectively [7, 8]. Besides, CTB used alone could
prevent the development of diabetes in NOD mice [9].
Studies have demonstrated that CTB can inhibit the acti-
vation of macrophage induced by lipopolysaccharide [10]
and induce the production of regulatory T (Treg) cells
[11]. Suppressing Th1-associated immune responses, en-
hancing Th2-associated immune responses, inhibiting the
activation of macrophage/microglia, and inducing Treg
cells are protective in stroke [12–14]. However, little is
known about whether CTB is beneficial for stroke. In the
present study, we investigated whether CTB had a neuro-
protective effect in the rat model of middle cerebral artery




Male Sprague–Dawley rats weighing 250–300 g (Labora-
tory Animal Center of Sun Yat-sen University, Guangzhou,
China) were housed in groups of four animals per cage
under controlled temperature (24.0 ± 2 °C) and a 12-h
light/dark cycle, with food and water available. The proto-
col was carried out according to the National Institute of
Health Guide for the Care and Use of Laboratory Animals.
The animals were randomly divided into four groups (n =
8 for each group): MCAO group, low dose group (animals
with MCAO and 0.4 mg/kg CTB treatment), high dose
group (animals with MCAO and 0.8 mg/kg CTB treat-
ment), CTB-sham group (animals with 0.8 mg/kg CTB
treatment), and sham operated group. Because separate
groups of animals were required for different tests and
time points, a total of 320 rats were used. In detail, nine
flocks of rats were used, one flock for TTC staining, two
flocks for the flow cytometry studies at 24 and 72 h,
respectively, two flocks for the qPCR, ELISA, and immu-
nohistochemistry at 24 and 72 h, respectively, two flocks
for microglia isolation from the ischemic hemisphere at 24
and 72 h, respectively, and two flocks for inactivation of
Treg cells by anti-CD25 at 24 and 72 h, respectively. Con-
sidering that the neurodeficit scores at 72 h were unavail-
able in three flocks because of sacrifice at 24 h and
inactivation of Treg cells could deteriorate ischemic stroke,
we presented the neurodeficit scores and body weights at
both 24 and 72 h of four flocks. For the same reason, when
analyzing mortality rate, the two flocks for inactivation of
Treg cells were not included.
Blinding was used at all stages throughout the study,
including neurodeficit scoring and sample and tissue
analysis.
Middle cerebral artery occlusion model
The food was withdrawn 12 h before the surgical pro-
cedure. The right MCAO was performed using an intra-
luminal filament model [15]. Briefly, the rats were
anesthetized with an intraperitoneal injection of 3 %
amobarbital (13 ml/kg). The right common carotid ar-
tery was exposed through a ventral midline neck inci-
sion. A monofilament (SUNBIO, China) was introduced
into the external carotid artery and advanced into the
circle of Willis via the internal carotid artery to occlude
the origin of the right middle cerebral artery. The fila-
ment was inserted 18–20 mm from the carotid bifur-
cation, confirmed with mild resistance. Successful
occlusion was confirmed by an 80–90 % reduction in
cerebral blood flow measured by laser Doppler flowme-
try. Ninety minutes after the induction of ischemia, the
rat was re-anesthetized to allow the withdrawal of the
filament and reperfusion was verified by laser Doppler
flowmetry. Then, the animals were returned to their
cages and given free access to food and water. CTB-
sham group and sham group rats went through all surgi-
cal procedures except the monofilament insertion.
During the surgery, rectal temperature was controlled at
37.0 °C with a heating pad. Body weights were measured
before surgery and at 24 and 72 h after MCAO. Inclusion
criteria were (1) successful occlusion and reperfusion and
(2) neurologic deficit score ≥1. Exclusion criteria were (1)
premature death and (2) cerebral hemorrhage or sub-
arachnoidal hemorrhage.
Drug administration
CTB (Sigma) was dissolved in saline to prepare concen-
trations of 0.5 mg/ml. For low dose group and high dose
group, CTB at doses of 0.4 and 0.8 mg/kg (added with
saline to a total volume of 1 ml) was administered re-
spectively by intraperitoneal injection, immediately after
cerebral ischemia and every 24 h for 3 days. For CTB-
sham group, CTB at doses of 0.8 mg/kg (added with
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saline to a total volume of 1 ml) was administered by in-
traperitoneal injection, immediately after cerebral ische-
mia and every 24 h for 3 days. We used high dose CTB
in CTB-sham group to make sure that the effect of CTB
treatment on baseline results of our study could be suffi-
ciently demonstrated. In the case of the MCAO and
sham operated group, equal volume saline was adminis-
tered in the same manner. To inactivate Treg cells,
300 μg of anti-CD25 was injected intraperitoneally 48 h
before ischemia induction.
Measurement of infarct volume
At 72 h after MCAO, the rats were sacrificed under deep
anesthesia with an overdose of pentobarbital (n = 8). To
quantify ischemic damage, brains were dissected and cut
into six coronal slices of 2-mm thickness, incubated in a
2 % solution of triphenyl tetrazolium chloride (TTC,
Sigma) at 37 °C for 15 min and immersion-fixed in a 4 %
paraformaldehyde. TTC-stained sections were photo-
graphed, and the digital images were analyzed using
Image-Pro Plus 5.1. The lesion volume was calculated by
multiplying the area by the thickness of slices. To com-
pensate for the effect of brain edema, percentage hemi-
sphere lesion volume (%HLV) was calculated by the
following equations [16]: %HLV = {[total infarct vol-
ume ‐ (right hemisphere volume ‐ left hemisphere volume)] /
left hemisphere volume} × 100 %.
Analysis of neurologic deficit scores
Neurological function was evaluated at 24 and 72 h after
MCAO. The deficits were scored on a modified scoring
system based on that developed by Longa et al. [15] as
follows: 0, no deficits; 1, difficulty in fully extending the
contralateral forelimb; 2, unable to extend the contralat-
eral forelimb; 3, mild circling to the contralateral side; 4,
severe circling; and 5, falling to the contralateral side.
Western blotting
For Western blotting analysis, the rats were sacrificed
immediately 24 h after MCAO. The cytosolic and nuclear
extracts from the ipsilateral cerebrum were prepared
according to the manufacturer’s instructions (Thermo).
Briefly, the tissue was homogenized in five volumes of
homogenization buffer A [20 mM N-2-hydroxyethylpiper-
azine-N′-2′-ethanesulfonic acid (HEPES), 1.5 mM MgCl2,
10 mM KCl, 1 mM EDTA, 1 mM ethylene glycol-bis(2-
aminoethyl ether) tetraacetic acid (EGTA), 250 mM su-
crose, 0.1 mM phenylmethanesulfonyl fluoride (PMSF),
1 mM dithiothreitol (DTT), and 10 μg/ml of each of apro-
tinin, pepstatin A, and leupeptin, pH 7.9]. The sample was
centrifuged at 750g at 4 °C for 15 min to separate the sam-
ple into supernatant A and pellet A. Pellet A, containing
the nuclear fraction, was resuspended in 90 μl of buffer B
(20 mM HEPES, 1.5 mM MgCl2, 20 mM KCl, 0.2 mM
EDTA, 0.5 mM EGTA, 0.2 mM PMSF, 0.5 mM DTT, and
10 μg/ml of each of aprotinin, pepstatin A, and leupeptin,
pH 7.9) and mixed with 30 μl of buffer C (20 mM HEPES,
1.2 mM KCl, 0.2 mM EDTA, 0.2 mM PMSF, 0.5 mM
DTT, and 10 μg/ml of each of aprotinin, pepstatin A, and
leupeptin, pH 7.9). The sample was placed on ice for
30 min during the extraction and then centrifuged at
12,000g for 30 min at 4 °C. The supernatant containing
the nuclear fraction was transferred and stored at −70 °C.
Supernatant A, containing the cytosolic protein, was fur-
ther centrifuged at 16,000g for 30 min at 4 °C to separate
supernatant B from pellet B. Supernatant B was used as
the cytosolic fraction and pellet B was discarded. Nuclear
pellet purity was assured by microscopic observation. To
exclude cross-contamination between the nuclear and
cytosolic fractions, specific antibodies of Lamin A (Santa
Cruz Biotechnology) and NF-kB (p50/p105) (eBioscience)
were used as individual markers for each fraction. The
Lamin A protein served as nuclear contamination marker
and the p105, the precursor of NF-kB p50, served as a
cytoplasmic contamination marker. The protein concen-
trations were determined using a BCA protein assay re-
agent kit (Novagen). As much as 30 μg of protein was
separated by SDS/PAGE, transferred 2 h to PVDF mem-
branes, the nonspecific binding of antibodies was blocked
with 5 % nonfat dried milk in PBS and then incubated
with the primary antibodies at 4 °C overnight: a rabbit
anti-rat NF-kB p65 antibody (1:2000, Millipore), a rabbit
anti-rat p-ERK1/2 antibody (1:1000, Cell Signaling Tech-
nology), a rabbit anti-rat β-actin (1:200, Millipore), and a
rabbit anti-rat histone H3 (1:100, Millipore). After three
washes with PBS containing 0.1 % Tween-20, the second
antibodies were incubated with membranes for 1 h at
room temperature. The relative density of bands was ana-
lyzed using an imaging densitometer (LI-COR Bioscience).
β-actin and histone H3 were used as an internal control
for the cytosolic and nuclear fractions, respectively.
EMSA
To determine the NF-kB binding activity in the ischemic
hemisphere, electrophoretic mobility shift assay (EMSA)
was performed. The oligonucleotides containing NF-kB
binding site (5′-AGTTGAGGGGACTTTCCCAGGC-3′)
and AP-1 binding site (5′-CGCTTGATGAGTCAGCCG
GAA-3′) were used as DNA probes (Promega). The DNA
probes were radio-labeled with [γ-32p] ATP using the T4
kinase according to the manufacturer’s instructions. For
binding reaction, the radio-labeled probes were incubated
with 5 μg of nuclear extracts. The binding buffer con-
tained 10 mM Tris–HCl (pH 7.5), 50 mM NaCl, 0.5 mM
EDTA, 1 mM DTT, 1 mM MgCl2, 4 % glycerol, and 2 μg
poly (dI-dC). The reaction mixtures were left at room
temperature to precede binding reaction 20 min. For
supershift assays, antibody to NF-kB was pre-incubated
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with nuclear extracts for 30 min at 4 °C before the addition
of radio-labeled probes. The final reaction mixtures were
analyzed in a 6 % nondenaturing polyacrylamide gel with
0.25× Tris-borate/EDTA as an electrophoresis buffer. The
specificity of binding was also examined by competition
assay with a 100-fold excess of nonlabeled NF-kB probes.
Nonspecific band was identified by changing the order of
addition, since the order of addition could influence non-
specific binding in gel shift assays. The figure was pre-
sented with minimum effect of nonspecific band.
Isolation of microglia/macrophage from the ischemic
hemisphere
Isolation of microglia/macrophage with preserved phe-
notypes was described in a previous study [17]. Briefly,
after perfusion with ice-cold PBS, the ischemic hemi-
sphere was dissected and enzymatically digested using
Neural Tissue Dissociation Kit (Miltenyi Biotec) for
35 min at 37 °C. Further processing was performed at
4 °C. Tissue debris was removed by passing the cell sus-
pension through a 40-μm cell strainer. Cells were resus-
pended in 30 % Percoll (GE Healthcare) and centrifuged
for 10 min at 700g. The supernatant containing the mye-
lin was removed, and the pelleted cells were washed with
HBSS. Then, cells were stained with PE-conjugated anti-
CD11b antibodies (Miltenyi Biotec) in IMAG buffer
(PBS supplemented with 0.5 % BSA and 2 mM EDTA)
for 10 min followed by incubation for 15 min with anti-
PE magnetic beads. CD11b+ cells were separated in a
magnetic field using MS columns (Miltenyi Biotec). The
amounts of antibodies and magnetic beads were calcu-
lated based on the number of cells obtained after myelin
removal, according to the manufacturer’s guidelines.
Cytokine enzyme-linked immunosorbent assay
Ischemic brain tissue were collected and frozen at −80 °C
immediately until analysis of cytokine protein concentra-
tions with commercial kits for the quantitative assay of
TNF-α, IL-1β, IL-17, IL-10, and TGF-β (RayBio). Individ-
ual ELISA was used for individual cytokines. For the active
form of TGF-β measurement, recombinant latent TGF-β
(1 μg/300 μl) was incubated with sTSP (3 μg/300 μl) for
5 min at 37 °C in a total volume of 300 μl of PBS in sili-
conized microcentrifuge tubes. The samples were then
tested for active TGF-β using a TGF-β ELISA Predicta kit.
The ELISA is selective for active TGF-β and only minim-
ally recognizes latent TGF-β.
RNA isolation and quantitative real-time PCR
To evaluate the cytokines and signaling molecules in
both transcriptive and translative levels, we conducted
real-time PCR to test the mRNA expressions after
measuring protein cytokine levels, so that the data were
more sufficient and convincing. The ischemic brain
tissue prepared by Percoll gradient centrifugation and
the microglia/macrophage isolated from the ischemic
hemisphere were lysed in RNAiso (Takara), respectively.
Real-time PCR was performed on cDNA samples using
SYBR Green qPCR SuperMix (Invitrogen). The primer se-
quences used in this study were as follows: TNF-α (primers,
sense 5′-TGA AGT AGT GGC CTG GAT TGC-3′; anti-
sense 5′-GAC ATT CCG GGA TCC AGT GA-3′), IL-1β
(primers, sense 5′-GTG CTG TCT GAC CCA TGT GA-
3′; antisense 5′-CAC AGG GAT TTT GTC GTT GCT-
3′), IL-17 (primers, sense 5′-CTC TGC AAA CTT CCT
TGT CT-3′; antisense 5′-GAA GGC AGA CAA TTC
TAA CC-3′), IL-10 (primers, sense 5′-TCT ACA AGG
CCA TGA ATG AG-3′; antisense 5′-GAG AGA GGT
ACA AAC GAG G-3′), TGF-β1 (primers, sense 5′-TGC
TTC AGC TCC ACA GAG AA-3′; antisense 5′-TGG
TTG TAG AGG GCA AGG AC-3′), NF-kB p65 (primers,
sense 5′-GAC GAT CTG TTT CCC CTC AT-3′; antisense
5′-GCT TCT CTC CCC AGG AAT AC-3′), ERK1
(primers, sense 5′-GGA CCG GAT GTT AAC CTT TA-
3′; antisense 5′-TGG TTC ATC TGT CGG ATC AT-3′),
ERK2 (primers, sense 5′-CGT ACC TGG AGC AGT ATT
ATG A-3′; antisense 5′-CCA GCT CCA TGT CAA ACT
TG-3′), β-actin as an internal standard (primers, sense 5′-
AGG GAA ATC GTG CGT GAC AT-3′; antisense 5′-
GAA CCG CTC ATT GCC GAT AG-3′). The reactions
were initially heated at 50 °C for 2 min; then at 95 °C for
2 min, 95 °C for 15 s, and 60 °C for 32 s, total of 40 cycles;
and finally stopped at 60 °C for 5 min. The relative gene
expression was calculated using the ΔΔCt method, the
samples were normalized to the expression of β-actin, and
the untreated sample was used as a calibrator.
Immunohistochemistry
Microglia activation was assessed by staining for Iba1
detected by immunohistochemical analysis. Rats were
deeply anesthetized at different time points and then
were perfused transcardially with normal saline followed
by ice-cold 4 % paraformaldehyde in phosphate-buffered
saline. Brain tissues were removed and fixed overnight
in 4 % paraformaldehyde at 4 °C and then immersed in
30 % sucrose. They were cut to 2-mm-thick coronal sec-
tions and embedded in paraffin and further sliced at a
thickness of 5 μm. The slides were deparaffinized, sequen-
tially rehydrated in graded alcohol, and then immersed in
PBS (pH 7.4). Slides were then microwaved for 2 min in
antigen unmasking solution, cooled, and washed three
times for 2 min in PBS. Sections were immersed for
25 min in 3 % hydrogen peroxide in distilled water to
eliminate endogenous peroxidase activity, then blocked in
immunohistochemical grade 1 % bovine serum albumin in
PBS for 1 h and diluted goat serum for 30 min to reduce
nonspecific staining. Sections were incubated overnight
with an anti-rat monoclonal antibody against Iba1 (Abcam).
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Peroxidase-conjugated anti-rabbit IgG (BD Biosciences)
was used as the secondary antibody (incubating for
30 min at 37 °C). Antibodies were detected using the
DAB kit (Boster, Wuhan, China) following the manufac-
turer’s instructions. Finally, the slides were observed
using a light microscope. In specimens, the positive cells
were counted in six selected areas of ischemic border
and the corresponding areas of contralateral hemispheres
for each case and expressed as the number of immuno-
positive cells/mm2.
Flow cytometry
The ischemic hemisphere and blood samples at various
time points after MCAO were collected for flow cyto-
metric analysis of leukocyte subpopulations. Individual
cell suspensions from the ischemic hemisphere and per-
ipheral mononuclear blood cells (PBMC) were prepared.
Rat antibodies were as follows (all from eBioscience):
FITC-labeled anti-rat CD4 antibodies, PE-labeled anti-
rat CD25 antibodies, PE-labeled anti-rat Foxp3 anti-
bodies, APC-labeled anti-rat CD3 antibodies, PE-labeled
anti-rat IL-17A antibodies, and FITC-labeled anti-rat
gamma delta TCR antibodies. Surface staining was per-
formed for 15 min with the corresponding mixture of
fluorescently labeled antibodies. After staining of surface
markers, cells were fixed, permeabilized using fixation
buffer in conjunction with permeabilization buffer
(eBioscience) and stained with antibodies anti-cytokines
and the corresponding isotype controls. For detection of
γδT cells, IL-17-producing γδT cells, and Th17 cells, indi-
vidual aliquots of 1 × 106 T cells were stimulated with
phorbol 12 myristate 13-acetate (PMA) (50 ng/ml; Sigma)
and ionomycin (1 μg/ml; Sigma) and in the presence of
monencin (1.7 μg/ml; Sigma) at 37 °C and 5 % CO2 for
4 h before they were collected and stained with antibodies.
FACS analysis was performed on a BD FACSAria and ana-
lyzed using FlowJo software.
Statistical analysis
All data in the text, tables, and figures are given as the
mean ± SD. Data were analyzed by a two-tailed t test or
one-way analysis of variance (ANOVA) followed by the
post hoc Student–Newman–Keuls (S–N–K) t test for
multiple comparisons. Qualitative data were analyzed
with the χ2 test, Differences were considered statistically
significant with p < 0.05. Statistical analyzes were carried
out using SPSS 17.0.
Results and discussion
CTB ameliorated neurological dysfunctions, mortality rate,
and body weight loss
Neurologic deficits, evaluated at 24 h after cerebral is-
chemia, were significantly reduced in low dose CTB
(CTB-L) group and high dose CTB (CTB-H) group
compared with MCAO group, respectively (CTB-L vs
MCAO, p = 0.001; CTB-H vs MCAO, p < 0.001; Fig. 1a).
And neurologic deficits were not significantly different
in the CTB-H group compared with the CTB-L group
(Fig. 1a). At 72 h after cerebral ischemia, neurologic def-
icits were significantly reduced in the CTB-L group and
the CTB-H group compared with the MCAO group,
respectively (CTB-L vs MCAO, p < 0.001; CTB-H vs
Fig. 1 Effect of CTB on neurological deficit scores, body weight, and infarct volume after MCAO. a Elevated neurological deficit scores after
MCAO were significantly attenuated by CTB, and neurologic deficits were significantly ameliorated in the CTB-H group compared with the CTB-L
group, both at 24 and 72 h. b CTB ameliorated body weight loss at 24 h after cerebral ischemia, while no significant difference was found
between the CTB-L group and CTB-H group. At 72 h after cerebral ischemia, body weight loss was significantly ameliorated by CTB, and body
weight loss in the CTB-H group was significantly less than that in the CTB-L group. c Quantification of infarct volume at 72 h. The ratio of
corrected infarct volume to the nonischemic hemisphere volume was calculated for the cerebral infarct size. Infarct volume was decreased at
72 h with CTB treatment and infarct volume was significantly reduced in the CTB-H group compared with the CTB-L group. d Representative TTC
stained brain sections of different groups were shown. Bars represent mean ± SD (n = 8); *p < 0.05 vs MCAO group, and #p < 0.05 vs CTB-L group
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MCAO, p < 0.001; Fig. 1a). And neurologic deficits were
significantly ameliorated in the CTB-H group compared
with the CTB-L group (p < 0.001; Fig. 1a). No rats
appeared with neurological impairment symptoms in the
sham group.
No rats died in the sham group. The mortality rates of
the MCAO group, CTB-L group, and CTB-H group
were 22.2 % (16/72), 13.8 % (9/65), and 6.7 % (4/60),
respectively, with significant difference (p = 0.041).
Similar with neurologic deficits, body weight loss at
24 h after cerebral ischemia was significantly ameliorated
in the CTB-L group and CTB-H group compared with
the MCAO group, respectively (CTB-L vs MCAO, p <
0.001; CTB-H vs MCAO, p < 0.001; Fig. 1b), while no
significant difference was found between the CTB-L
group and CTB-H group (Fig. 1b). At 72 h after cerebral
ischemia, body weight loss was significantly ameliorated
in the CTB-L group and CTB-H group compared with
the MCAO group, respectively (CTB-L vs MCAO, p <
0.001; CTB-H vs MCAO, p < 0.001; Fig. 1b). And body
weight loss in the CTB-H group was significantly less
than that in the CTB-L group (p < 0.001; Fig. 1b).
CTB reduced brain infarction
Infarct volume was measured by TTC at 72 h after cere-
bral ischemia. Infarct volumes in both the CTB-L group
and CTB-H group were significantly reduced compared
with the MCAO group, respectively (CTB-L vs MCAO,
p < 0.001; CTB-H vs MCAO, p < 0.001; Fig. 1c, d). And
infarct volume in the CTB-H group was significantly
smaller than that in the CTB-L group (p < 0.001, Fig. 1c, d).
CTB downregulated pro-inflammatory cytokines in the
ischemic brain and microglia/macrophage isolated
from the ischemic hemisphere and upregulated
anti-inflammatory cytokine in the ischemic brain
To confirm whether CTB was immunomodulatory in
experimental stroke, we tested the levels of several pro-
and anti-inflammatory cytokines, including IL-1β, TNF-
α, IL-17, TGF-β, and IL-10. The concentrations of IL-1β
and TNF-α were measured by ELISA at 24 h after cere-
bral ischemia. The concentrations of IL-17, TGF-β, and
IL-10 were measured by ELISA at 24 and 72 h after
cerebral ischemia. In the ischemic brain, CTB treatment
dose-dependently downregulated the levels of IL-1β,
TNF-α, and IL-17, while the levels of TGF-β and IL-10
were unchanged at 24 h but dose-dependently upregu-
lated at 72 h (Fig. 2).
RT-PCR was used to assess the gene expressions in
ischemic brain of IL-1β, TNF-α, IL-17, TGF-β, and IL-10
at the same time points as those in ELISA test. CTB
treatment suppressed the gene expressions of IL-1β,
TNF-α, and IL-17 (Fig. 3a–c), enhanced the gene ex-
pressions of TGF-β and IL-10 at 72 h (Fig. 3d, e), in a
dose-dependent manner. Besides, CTB dose-dependently
suppressed the mRNA expression of IL-1β and TNF-α
in microglia/macrophage isolated from the ischemic
hemisphere at 24 h (Fig. 4).
Inactivation of Treg cells deprived the increase of TGF-β
and IL-10 in the ischemic brain induced by CTB
To find out whether CTB increased the levels of TGF-β
and IL-10 in the ischemic brain by induction of Treg
cells, anti-CD25 pretreatment was conducted to inacti-
vate Treg cells. Anti-CD25 pretreatment had no impact
on the protein and mRNA levels of TGF-β and IL-10 at
24 h (Fig. 2d, e). The up-regulations of TGF-β and IL-10
at 72 h were attenuated by anti-CD25 pretreatment,
both in CTB-L group and CTB-H group (Fig. 3d, e).
CTB downregulated the expression of NF-kB p65 and
binding activity of NF-kB, did not affect ERK1/2 expression,
but suppressed ERK1/2 phosphorylation
To investigate whether CTB induced immunomodula-
tion by affecting NF-kB p65 and ERK1/2 pathway, we
measured the levels of NF-kB p65 (including cytosolic
fraction and nuclear farction), ERK1/2, and p-ERK1/2 by
Western blotting, the binding activity of NF-kB by
EMSA, and the gene expression of NF-kB p65, ERK1,
and ERK2 by RT-PCR in the ischemic brain at 22.5 h
after reperfusion. The results of Western blotting showed
that CTB treatment dose-dependently downregulated the
levels of cytosolic NF-kB p65, nuclear NF-kB p65 in the
ischemic brain (Fig. 5a, b). CTB treatment did not affect
ERK1/2 expression, but dose-dependently suppressed
ERK1/2 phosphorylation in the ischemic brain (Fig. 5c).
The results of EMSA showed that CTB treatment
dose-dependently inhibited the binding activity of NF-kB
in the ischemic brain (Fig. 6).
The results of RT-PCR indicated that CTB treatment
dose-dependently suppressed the gene expression of
NF-kB p65 in the ischemic brain (Fig. 3f), but did not
affect the gene expression of ERK1 and ERK2 (Fig. 3g, h).
CTB suppressed the activation of microglia/macrophage
induced by cerebral ischemia
At 24 h after ischemia, the activation of microglia/macro-
phage stained by Iba1 around the infarct border in the
MCAO group was markedly enhanced compared with that
in the control group (Fig. 7). Treatment with CTB dose-
dependently suppressed the expression of Iba1 (Fig. 7).
Effects of CTB on the dynamic changes of Treg cells, γδT
cells, IL-17-producing γδT cells, and Th17 cells
In the peripheral blood, Treg cells were decreased at
24 h and increased at 72 h after cerebral ischemia
(Fig. 8a). In the ischemic hemisphere, no change of Treg
cells was found at 24 h and an increase was detected at
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72 h after cerebral ischemia (Fig. 8b). CTB dose-
dependently compensated the decrease at 24 h and
further increased Treg cells at 72 h in the peripheral
blood after cerebral ischemia (Fig. 8a). In the ischemic
hemisphere, CTB did not alter the percentage of Treg
cells at 24 h, but dose-dependently increased Treg cells
at 72 h after cerebral ischemia (Fig. 8b).
In contrast with Treg cells, γδT cells were increased in
peripheral blood at 24 h after cerebral ischemia, while
they were decreased to a level lower than that of sham
group at 72 h (Fig. 8c). In the ischemic hemisphere, γδT
cells increased at 24 h and further at 72 h after cerebral
ischemia (Fig. 8d). CTB dose-dependently suppressed
the increase of γδT cells in peripheral blood at 24 h after
cerebral ischemia, while it had no effect on the decrease
of γδT cells at 72 h (Fig. 8c). In the ischemic hemisphere,
the increases of γδT cells at 24 h and 72 h after cerebral
ischemia were suppressed by CTB in a dose-dependent
manner (Fig. 8d). To confirm the source of IL-17 in the
ischemic hemisphere, IL-17-producing γδT cells and
Th17 cells were tested. The dynamic changes of IL-17-
producing γδT cells in the ischemic hemisphere with or
without CTB treatment were corresponding to those of
γδT cells (Fig. 8e). In the ischemic hemisphere, no
change of Th17 cells was found at 24 h and 72 h, and
CTB treatment had no effect on Th17 cells (Fig. 8f ).
Effects of CTB on baseline values of cytokines,
transcription factors, and peripheral cells
Considering the immune nature of CTB, the CTB-sham
group was set up to evaluate the effects of CTB on base-
line values of cytokines and peripheral cells. In brain,
CTB did not affect the levels of IL-1β, TNF-α, IL-17,
TGF-β, IL-10, NF-kB p65, ERK1, and ERK2 (Figs. 2 and
3). Besides, CTB had no effect on Treg cells and γδT
cells in the brain (Fig. 8b, d). In the peripheral blood,
CTB increased Treg cells at both 24 and 72 h (Fig. 8a),
while it did not affect γδT cells (Fig. 8c).
Immunity plays an important role in the pathogenesis
of ischemic stroke. The immune-inflammatory response
in stroke begins within the brain and its vessels. The
first immune cells that respond to these events seem
Fig. 2 Effect of CTB on cytokine expression in the ischemic brain after MCAO. a The level of IL-1β in the sham ischemic hemisphere of the CTB-
sham group was not significantly different from that of the sham group. CTB dose-dependently downregulated the levels of IL-1β in the ischemic
brain at 24 h after ischemia. b The level of TNF-α in the sham ischemic hemisphere of the CTB-sham group was not significantly different from
that of the sham group. CTB dose-dependently downregulated the levels of TNF-α in the ischemic brain at 24 h after ischemia. c The levels of IL-17 in
the sham ischemic hemisphere of the CTB-sham group at 24 and 72 h after ischemia were not significantly different from those of the sham group at
24 and 72 h after ischemia, respectively. CTB dose-dependently downregulated the levels of IL-17 in the ischemic brain both at 24 and 72 h after
ischemia. d The levels of IL-10 in the sham ischemic hemisphere of the CTB-sham group at 24 and 72 h after ischemia were not significantly different
from those of the sham group at 24 and 72 h after ischemia, respectively. CTB did not affect the levels of IL-10 at 24 h after ischemia, while it dose-
dependently upregulated the levels of IL-10 at 72 h after ischemia. Anti-CD25 pretreatment had no impact on the levels of IL-10 at 24 h, while it
attenuated the up-regulations of IL-10 at 72 h after ischemia, both in the CTB-L group and CTB-H group. e The levels of TGF-β in the sham ischemic
hemisphere of the CTB-sham group at 24 and 72 h after ischemia were not significantly different from those of the sham group at 24 and 72 h after
ischemia, respectively. CTB did not affect the levels of TGF-β at 24 h after ischemia, while it dose-dependently upregulated the levels of TGF-β at 72 h
after ischemia. Anti-CD25 pretreatment had no impact on the levels of TGF-β at 24 h, while it attenuated the up-regulations of TGF-β at 72 h after
ischemia, both in the CTB-L group and CTB-H group. Bars represent mean ± SD (n = 8); *p < 0.05 vs MCAO group, and #p < 0.05 vs CTB-L group
Zhang et al. Journal of Neuroinflammation  (2016) 13:147 Page 7 of 14
Fig. 3 Effect of CTB on the mRNA expression of cytokines and transcriptional factors in the ischemic brain after MCAO. a The level of IL-1β mRNA
expression in the sham ischemic hemisphere of the CTB-sham group was not significantly different from that of the sham group. CTB dose-
dependently downregulated the level of IL-1β mRNA expression in the ischemic brain. b The level of TNF-α mRNA expression in the sham
ischemic hemisphere of the CTB-sham group was not significantly different from that of the sham group. CTB dose-dependently downregulated
the level of TNF-α mRNA expression in the ischemic brain. c The levels of IL-17 mRNA expression in the sham ischemic hemisphere of the CTB-
sham group at 24 and 72 h after ischemia were not significantly different from those of the sham group at 24 and 72 h after ischemia, respect-
ively. CTB dose-dependently downregulated the levels of IL-17 mRNA expression in the ischemic brain both at 24 and 72 h after ischemia. d The
levels of IL-10 mRNA expression in the sham ischemic hemisphere of the CTB-sham group at 24 and 72 h after ischemia were not significantly
different from those of the sham group at 24 and 72 h after ischemia, respectively. CTB did not affect the levels of IL-10 mRNA expression at 24 h
after ischemia, while it dose-dependently upregulated the levels of IL-10 mRNA expression at 72 h after ischemia. Anti-CD25 pretreatment had no
impact on the levels of IL-10 mRNA expression at 24 h, while it attenuated the up-regulations of IL-10 mRNA expression at 72 h after ischemia,
both in the CTB-L group and CTB-H group. e The levels of TGF-β mRNA expression in the sham ischemic hemisphere of the CTB-sham group at
24 and 72 h after ischemia were not significantly different from those of the sham group at 24 and 72 h after ischemia, respectively. CTB did not
affect the levels of TGF-β mRNA expression at 24 h after ischemia, while it dose-dependently upregulated the levels of TGF-β mRNA expression at
72 h after ischemia. Anti-CD25 pretreatment had no impact on the levels of TGF-β mRNA expression at 24 h, while it attenuated the up-regulations of
TGF-β mRNA expression at 72 h after ischemia, both in the CTB-L group and CTB-H group. f The level of NF-kB p65 mRNA expression in the sham
ischemic hemisphere of the CTB-sham group was not significantly different from that of the sham group. CTB dose-dependently downregulated the
level of NF-kB p65 mRNA expression in the ischemic brain. g The level of ERK1 mRNA expression in the sham ischemic hemisphere of the CTB-sham
group was not significantly different from that of the sham group. CTB did not affect the level of ERK1 mRNA expression in the ischemic brain. h The
level of ERK2 mRNA expression in the sham ischemic hemisphere of the CTB-sham group was not significantly different from that of the sham group.
CTB did not affect the level of ERK2 mRNA expression in the ischemic brain. Bars represent mean ± SD (n = 8); *p < 0.05 vs MCAO group, and #p < 0.05
vs CTB-L group
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to be brain-intrinsic microglia, followed by leukocytes
and lymphocytes that enter the brain from the per-
iphery. The proteins that these cells produce have an
important role in cell death and in the enlargement
of brain lesions that result from stroke [18]. The immune
response can also contribute to pathogenesis before the
onset of stroke: aberrant immune responses can induce
inflammation within and around vessel walls, thereby pro-
moting thrombosis, altering vascular reactivity, and en-
couraging atherosclerosis [19]. Leukocytes contribute to
the growth of atherosclerotic plaques, leading to inflam-
mation, instability, and rupture, and occlusion of arteries
by atherosclerotic plaques leads to ischemic events [20].
Several controlled trials have assessed the efficacy of
various immunomodulatory drugs in patients with is-
chemic stroke, such as anti-ICAM-1 antibody [21],
minocycline [22], and fingolimod [23]. On the other
hand, stroke has a marked impact on the immune sys-
tem. Within days of stroke, patients develop lympho-
penia [24]. The volume of the cerebral infarction has
been directly associated with the extent of lymphocy-
topenia and monocyte dysfunction [25]. The down-
regulation of immune responses that originates in the
injured brain avoids autoimmunity against brain anti-
gens that are released during cell death. However,
post-stroke immunosuppression raise the incidence of
infection which is associated with the increase of mor-
tality [26].
CTB is a potent immunomodulator and has been stud-
ied as a therapy for autoimmune diseases in animal
models, such as experimental autoimmune encephalo-
myelitis and diabetes [7, 9]. However, little is known
about whether CTB is beneficial for stroke. In the
present study, we clearly demonstrated that CTB pro-
tected the brain against ischemia and reperfusion injury
in a rat MCAO model. CTB significantly ameliorated
neurological deficits and cerebral infarct volume with a
dose-effect relation. This protection was correlative with
the anti-inflammation effect of CTB.
Increased expression cytokines play an important role
in inflammatory response followed cerebral ischemia. Is-
chemia leads to rapid up-regulation of pro-inflammatory
cytokines, such as TNF-α and IL-1β [14, 27]. In mice, in-
tracerebroventricular injection of TNF-α or IL-1β en-
hances brain ischaemic damage [28, 29]. Researchers
also found that the injection of antagonists of TNF-α
and IL-1β relieved the ischemia injury [28, 30]. Experi-
mental data have shown that resident microglia are
activated within minutes of ischemia onset and produce
TNF-α and IL-1β [31, 32], subsequent infiltrating
macrophage also contribute the production of TNF-α
and IL-1β. Inhibiting microglia/macrophage activation
has been shown to protect brain against focal cerebral
ischemia [14]. Our study showed that CTB treatment
markedly suppressed the elevation of TNF-α and IL-1β
in both ischemic brain and the microglia/macrophage
isolated from the ischemic hemisphere, and microglia/
macrophage activation was also inhibited. So one of the
neuroprotective mechanisms of CTB might be attributed
to the decrease of TNF-α and IL-1β via inhibiting micro-
glia/macrophage activation.
IL-17 is another powerful pro-inflammatory cytokine.
Th17 cells and γδT cells are considered as two major
sources of IL-17. Experimental evidence demonstrated
that the main source of IL-17 in the ischemic brain was
γδT cells which could reach the damaged cerebral hemi-
sphere as early as 6–12 h after ischemia and peaked at
3 days [33]. Our results also showed that the dynamic
change of IL-17 in the ischemic brain was paralleled
with that of γδT cells and IL-17-producing γδT cells;
meanwhile, no change of Th17 cells was detected,
suggesting that CTB reduced IL-17 by suppressing γδT
Fig. 4 Effect of CTB on mRNA expression of cytokines in microglia/macrophage isolated from the ischemic hemisphere. a CTB dose-dependently
downregulated the level of IL-1β mRNA expression in microglia/macrophage isolated from the ischemic hemisphere at 24 h. b CTB dose-dependently
downregulated the level of TNF-α mRNA expression in microglia/macrophage isolated from the ischemic hemisphere at 24 h. Bars represent mean ±
SD (n = 8); *p < 0.05 vs MCAO group, and #p < 0.05 vs CTB-L group
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Fig. 6 CTB treatment dose-dependently inhibited the binding activity of NF-kB in the ischemic hemisphere at 24 h after ischemia. Band 1: SHAM;
band 2: MCAO; band 3: CTB-L; band 4: CTB-H. Bars represent mean ± SD (n = 8); *p < 0.05 vs MCAO group, and #p < 0.05 vs CTB-L group
Fig. 5 Effect of CTB on expression of cytosolic NF-kB p65, nuclear NF-kB p65, ERK1/2, and p-ERK1/2 in the ischemic brain after MCAO. a CTB
dose-dependently downregulated the level of cytosolic NF-kB p65 expression in the ischemic brain. b CTB dose-dependently downregulated
the level of nuclear NF-kB p65 expression in the ischemic brain. c CTB did not affect the level of ERK1/2 expression in the ischemic brain, but
dose-dependently suppressed ERK1/2 phosphorylation. Bars represent mean ± SD (n = 8); *p < 0.05 vs MCAO group, and #p < 0.05 vs CTB-L group
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cells. CTB suppressed the increase of γδT cells in the
peripheral blood at 24 h after ischemia, indicating that
CTB might prevent the release of γδT cells from im-
mune organs to blood so less γδT cells could infiltrate
into the brain. Previous studies have demonstrated that
blockade of T cell infiltration into the brain reduced
cerebral ischemic damage [13, 33], indicating that γδT
cells deteriorate ischemic stroke by migrating to the
brain instead of signaling from outside of the brain.
Therefore, we proposed that CTB improved stroke by
inhibiting the infiltration of γδT cells into the brain in-
stead of suppressing the increase of γδT cells in the per-
ipheral blood.
The outcome of post-ischemic inflammatory processes
mainly depends on the imbalance between the activation
of pro-inflammatory cytokine cascade and the induction
of anti-inflammatory cytokines [34]. IL-10 and TGF-β
are two major anti-inflammatory cytokines and could
ameliorate experimental stroke [35]. It has been demon-
strated that Treg cells reached the ischemic brain at sev-
eral days after ischemia and exerted protective effect by
secreting IL-10 and TGF-β [13]. In our study, the dy-
namic changes of IL-10 and TGF-β in the ischemic brain
were consistent with that of Treg cells. So CTB might
increase IL-10 and TGF-β in the ischemic brain by
inducing more Treg cells migrating into the infarct area.
Inactivation of Treg cells attenuated the raise of IL-10,
and TGF-β also indicated that the major source of these
cytokine increments was Treg cells. Besides, since CTB
could induce the production of Treg cells, the increase
of Treg cells in the peripheral blood might also contrib-
ute to the increase of Treg cells infiltrating into the
ischemic brain. Although CTB had no effect on γδT cells
at 72 h in the peripheral blood after cerebral ischemia,
there is still the risk of enhancing the post-stroke
immunodeficiency since Treg cells were increased. It has
been demonstrated that TGF-β is induced in response
to focal cerebral ischemia [36]. Different brain cells,
including neurons, astrocytes, and microglias, can secrete
TGF-β after MCAO [37]. Our results also showed that the
level of TGF-β in the ischemic brain tissue of the MCAO
group was higher than that of the sham group. The up-
regulation of TGF-β could last more than 1 week after
stroke [38]. Many researches have shown the neuroprotec-
tive effect of TGF-β in stroke; however, increment of
TGF-β during chronic injury leads to reactive astrogliosis.
Astrogliosis may have a detrimental effect on recovery
due to astrocytes extending processes in the infarct
border to encompass the developing infarct, thereby
inhibiting neuronal plasticity and the formation of new
axons and blood vessels in the infarcted region [39].
Therefore, it seems that a short-term usage of CTB
might be reasonable.
NF-kB, a pivotal transcription factor, is essential for
immune and stress responses within the brain. It is com-
posed of subunits p65 and p50. When cells are stimu-
lated, NF-kB is activated and translocated into the
nucleus, inducing transcriptional activation of potentially
deleterious pro-inflammatory genes, such as TNF-α and
IL-1β [40]. In rodents, activation of NF-kB occurs after
experimental stroke, and inhibiting the NF-kB signaling
pathway by pharmacological and genetic approaches has
been reported to be neuroprotective in the model of
experimental stroke [40, 41]. One mechanism respon-
sible for NF-kB induction involves the stimulation of the
mitogen-activated protein kinase (MAPK) pathways.
Three members of the MAPK family, ERK1/2, SAPK/
JNK, and p38, are all activated early after focal cerebral
ischemia, and inhibition of this pathway reduces the ex-
pression of proinflammatory cytokines and confers pro-
tection against the insult [42]. In this study, we found
that CTB treatment did not affect ERK1/2 expression,
but suppressed ERK1/2 phosphorylation. NF-kB expres-
sion was downregulated, and its translocation into the
nucleus was also suppressed. Besides, the binding activ-
ity of NF-kB was inhibited. Therefore, we hypothesized
Fig. 7 Immunohistochemistry for Iba1 in CTB dose-dependently suppressed microglia/macrophage activation at 24 h after ischemia in ischemic
border. Bars represent mean ± SD (n = 8); *p < 0.05 vs MCAO group, and #p < 0.05 vs CTB-L group. Original magnification ×400
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Fig. 8 (See legend on next page.)
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that CTB affects the NF-kB pathway by inhibiting
ERK1/2 phosphorylation, although we could not exclude
that SAPK/JNK and p38 were simultaneously involved.
It was reported that neuronal NF-kB inhibition reduced
stroke size and apoptosis [10]. It was also shown that
over-expression of NF-kB-p65 in astrocytes significantly
increased the co-cultured neuronal apoptosis under
oxygen-glucose deprivation followed by oxygen-glucose
regeneration condition [31]. In addition, suppression of
NF-kB in microglia attenuated the severity of experi-
mental stroke [32]. So it is unclear that CTB downregu-
lated NF-kB in which cell types.
The increment of peripheral Treg cells in the CTB-
sham group reflected the immune tolerance induced by
CTB. Since the blood-brain barrier was not damaged,
Treg cells in the brain did not increase. On the other
side, the reason for γδT cells being not suppressed might
be that these cells were not in activating state in the
CTB-sham group. No changes of the levels of cytokines
and transcription factors in the brain of CTB-sham
group were found, indicating that CTB might only have
impact on the brain with inflammation.
Finally, we have concerns about the pros and cons of
using CTB as a potential clinical therapy to stroke. CTB
did ameliorate ischemic stroke by immunomodulation.
However, it should be noted that stroke per se could
lead to immunosupression which promotes spontaneous
bacterial infections [43]. And infection is an independent
risk factor for poor outcome after acute ischemic stroke
[44]. So it is possible that CTB might increase infection
after stroke by enhancing immunodeficiency, and this
impact might be attenuated by the specific pathogen-
free environment in which our study was done. There-
fore, further research is required to evaluate the risk of
raising infection after stroke by CTB.
Conclusions
Administration of CTB decreased neurologic impairment
and tissue injury after cerebral ischemia via its immu-
nomodulatory functions, including inhibiting microglia/
macrophage activation, suppressing γδTcells, and inducing
production of Treg cells, thus regulating the secretion
of related cytokines. Suppression of NF-kB and ERK1/
2 pathways is involved in the neuroprotective mech-
anism of CTB.
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Fig. 8 Effect of CTB on Treg cells, γδT cells, IL-17-producing γδT cells, and Th17 cells. a Treg cells in the peripheral blood of the CTB-sham group
were significantly increased both at 24 and 72 h after ischemia, compared with those of the sham group. CTB dose-dependently increased Treg
cells in the peripheral blood both at 24 and 72 h after ischemia. b Treg cells in the sham ischemic hemisphere of the CTB-sham group both at 24
and 72 h after ischemia were not significantly different from those in the sham ischemic hemisphere of the sham group. In the ischemic hemisphere,
CTB did not alter the percentage of Treg cells at 24 h, but a dose-dependent increase was found at 72 h after ischemia. c γδT cells in the peripheral
blood of CTB-sham group both at 24 and 72 h after ischemia were not significantly different from those of the sham group. CTB dose-dependently
suppressed the increase of γδT cells at 24 h, while it did not affect the proportion of γδT cells at 72 h after ischemia in the peripheral blood. d γδT cells
in the sham ischemic hemisphere of the CTB-sham group both at 24 and 72 h after ischemia were not significantly different from those in the sham
ischemic hemisphere of the sham group. In the ischemic hemisphere, the increases of γδT cells at 24 and 72 h after ischemia were dose-dependently
suppressed by CTB. e In the ischemic hemisphere, the increases of IL-17-producing γδT cells at 24 and 72 h after ischemia were dose-dependently
suppressed by CTB. f In the ischemic hemisphere, CTB had no effect on the Th17 cells at 24 and 72 h after ischemia. Bars represent mean ± SD (n = 8);
*p < 0.05 vs MCAO group, #p < 0.05 vs CTB-L group, and &p < 0.05 vs SHAM group
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